CYP17A1
ENSG00000148795
Target class
Enzyme
Chromosome
10
Approved drugs
2
Clinical candidates (approved and in development)
6
- Approved drugs
- 2
- Clinical candidates (approved and in development)
- 6
- Chemical probe available
- No
- Target name
- CYP17A1
- Gene name
- Cytochrome P450 family 17 subfamily A member 1
- Gene symbol
- CYP17A1
- Previous gene symbols
- CYP17
- Protein name
- Steroid 17-alpha-hydroxylase/17,20 lyase (EC 1.14.14.19) (17-alpha-hydroxyprogesterone aldolase) (EC 1.14.14.32) (CYPXVII) (Cytochrome P450 17A1) (Cytochrome P450-C17) (Cytochrome P450c17) (Steroid 17-alpha-monooxygenase)
- P450C17
- CPT7
- S17AH
- Gene biotype
- Protein coding
- Gene family
- Cytochrome P450 family 17
- Target class
- Enzyme
- Target type
- Human gene
- Tissues expressed in
- 19
- Protein localisation evidence grade
- Approved
- Highest tissue expression
- 6,921.5
- Tissue specificity (Gini)
- 0.976
- Tissue specificity (tau)
- 1
- KEGG gene identifiers
- hsa:1586
- Protein interaction confidence
- 0.907896
- Protein interaction partners
- 48
- R-HSA-193048
- R-HSA-194002
- R-HSA-5579028
- End position
- 102837501
- Start position
- 102830461
- Chromosome
- 10
- Strand
- Reverse
- Endoplasmic reticulum membrane . Microsome membrane .
- Vesicles
Publication evidence
- PubMed 2808364
- Tissue specificity (tau)
- 0.999797
- Expression inequality (Gini)
- 0.976277
Expression in transcripts per million
- Adrenal Gland
- 6,921.5
- Testis
- 14.57
- Thyroid
- 6.31
- Kidney - Medulla
- 4.73
- Kidney - Cortex
- 4.72
Expression in transcripts per million
- Adrenal Gland6,921.5
- Testis14.57
- Thyroid6.31
- Kidney - Medulla4.73
- Kidney - Cortex4.72
- Nerve - Tibial2.43
- Fallopian Tube2.24
- Ovary2.11
- Cervix - Ectocervix2.11
- Liver1.95
- Brain - Cerebellum1.93
- Brain - Cerebellar Hemisphere1.62
- Cervix - Endocervix1.59
- Artery - Aorta1.38
- Artery - Tibial1.32
- Muscle - Skeletal1.3
- Artery - Coronary1.26
- Uterus1.21
- Vagina1
- Prostate0.94
- Pituitary0.92
- Stomach0.9
- Breast - Mammary Tissue0.87
- Lung0.84
- Spleen0.81
And 29 more, listed on the interactive page.
- GO:0006694
- GO:0006702
- GO:0006704
- GO:0007548
- GO:0008202
- GO:0034651
- GO:0042446
- GO:0042448
Cellular components
- GO:0005789
- GO:0004508
- GO:0019825
- GO:0020037
Related records
Trials (389)
- 177Lu-PSMA-I&T for Metastatic Castration-Resistant Prostate Cancer
- 1911GCCC: Galeterone With Gemcitabine for Patients With Metastatic Pancreatic Adenocarcinoma
- 3-arm Study of Abiraterone Acetate Alone, Abiraterone Acetate Plus Degarelix, a GnRH Antagonist, and Degarelix Alone for Patients With Prostate Cancer With a Rising PSA or a Rising PSA and Nodal Disease Following Definitive Radical Prostatectomy
- A 2 Part, Phase 2 Trial of Galeterone in the Treatment of Castration Resistant Prostate Cancer
- A Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDeate-Prostate02)
- A Clinical Study of QLC5508 and/or QLH12016 in Combination With Other Anti-tumor Therapies in Subjects With Advanced Prostate Cancer
- A Comparative Dose-finding Study of RS-113 in Patients With Metastatic Castration-resistant Prostate Cancer
- A Comparative Study of Bioavailability of 3 New Abiraterone Acetate Tablets With Current Commercial Tablet
- A Drug-Drug Interaction Study of Abiraterone Acetate Plus Prednisone With Dextromethorphan and Theophylline in Patients With Metastatic Castration-Resistant Prostate Cancer
- A Multi-Center Trial of Androgen Suppression With Abiraterone Acetate, Leuprolide, PARP Inhibition and Stereotactic Body Radiotherapy in Prostate Cancer
- A Multi-centre Study to Assess the Safety, Tolerability, and Pharmacokinetics of Capivasertib (AZD5363) in Combination With Novel Agents in Patients With Metastatic Prostate Cancer
- A Multicenter Phase I/II Trial of Abiraterone Acetate + BEZ235 in Metastatic, Castration-Resistant Prostate Cancer
- A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study of Fuzuloparib Combined With Abiraterone Acetate and Prednisone (AA-P) Versus Placebo Combined With AA-P as First-Line Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer
- A Novel Insight Into CRPC Progression and Immune: Evidence From Single-cell Spatial Transcriptome Multi-omics
- A Pharmacokinetic Study of Abiraterone Acetate in Male Participants With Impaired Renal Function Compared to Individuals With Normal Renal Function
- A Pharmacokinetics Study to Assess Abiraterone Acetate Capsule and Tablet Formulations in Patients With Prostate Cancer
- A Phase 1 Clinical Study of AZD4635 in Patients With Advanced Solid Malignancies
- A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors
- A Phase 1/2a Study of the 2S,4R Enantiomer of Ketoconazole in Subjects With Type 2 Diabetes Mellitus
- A Phase 2 Study to Evaluate Safety and Efficacy of Abiraterone Acetate in Male Participants With Prostate Cancer
Drugs (6)
- Abiraterone Cytochrome P450 17A1 inhibitor
- Abiraterone acetate Cytochrome P450 17A1 inhibitor
- Galeterone Cytochrome P450 17A1 inhibitor
- Levoketoconazole Cytochrome P450 17A1 inhibitor
- Orteronel Cytochrome P450 17A1 inhibitor
- Seviteronel Cytochrome P450 17A1 inhibitor